Lyon, March 28^th – Advanced BioDesign announced today it will present updated results of its second generation of ALDH1 inhibitor, ABD0171, at the upcoming AACR conference in Chicago, Illinois. The poster presentation will provide proof of concept of the strong synergistic effect of ABD0171 in combination with anti-PD-1 therapy in microsatellite stable (MSS) colorectal cancer, a subtype representing 80% of colorectal cancers, known for its poor responsiveness to immunotherapy.

The combination therapy effectively reshapes the tumour immune microenvironment by reducing key immunosuppressive cell populations, thereby enhancing anti-tumour immunity and restoring responsiveness to immunotherapy. Additionally, Advanced BioDesign identified a potential plasma biomarker predictive of therapeutic response, further highlighting ABD0171’s promise in addressing this critical unmet medical need. 

Details of the poster presentation at AACR 2025 are: 

Late-breaking abstract title: Selective and novel ALDH1 inhibitor enhances immune checkpoint blockade therapy in preclinical models of MSS colorectal cancer 
Session: PO.IM01.09 Overcoming Checkpoint Inhibition and Tumor Suppression
Abstract number: 73026 
Presenter: Akinchan Kumar, Luxembourg Institute of Health, Luxembourg City, Luxembourg 
Authors: Akinchan Kumar, Andrada Constantinescu, Ismail Ceylan, Mileidys Perez-Alea, Bassam Janji 
Date: Wednesday, April 30th, 2025 
Time: 9:00 am – 12:00 pm EST 
Location: Poster Section 39

About Xerys Invest  

Xerys Invest is a French private equity firm that invests mainly in today’s significant sectors such as Health & Life Sciences and GreenTech. Xerys Invest thus supports companies in industrial sectors that are going through major transformations that meet economic, environmental, and societal challenges and that have strong ambitions in terms of development and international expansion. Xerys Invest stands out on the market both by its modus operandi and long-term strategic and operational support for the companies held in its portfolio and by its offer of traced or pooled investment opportunities offered to investors and the relationship with them. Finally, Xerys Invest has real sector expertise, supported by a strategic committee made up of specialists and recognized experts in key sectors. For more information: https://xerys.com; LinkedIn @Xerys. 

About Advanced BioDesign 

Advanced BioDesign is a French biotechnology company developing an innovative new therapeutic approach against resistant cancers, with a first indication in acute myeloid leukemia (AML). Its first drug candidate, ABD-3001, is a first-in-class « suicide » inhibitor of class 1 aldehyde dehydrogenases (ALDH1). In January 2022, Advanced BioDesign obtained authorization from the French Agence Nationale de Sécurité du Médicament (ANSM) to launch its first human clinical trial, ODYSSEY, which began in November 2022. Based in Lyon, Advanced BioDesign is supported and accompanied by Xerys Invest funds, which have been financing its research and development programs since 2013. 

For more information: https://www.a-biodesign.com; LinkedIn @Advanced BioDesign  

Contacts:

Advanced BioDesign

Ismail Ceylan ismail.ceylan@a-biodesign.com

PR_AACR_28042025 Télécharger